This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Efficacy of Metformin in Lean Women With Polycystic Ovary Syndrome

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified October 2006 by Aarhus University Hospital Skejby.
Recruitment status was:  Not yet recruiting
Aarhus University Hospital
Information provided by:
Aarhus University Hospital Skejby Identifier:
First received: April 26, 2006
Last updated: October 10, 2006
Last verified: October 2006
Insulin resistance is an important feature of the polycystic ovary syndrome,and patiens are successfully treated with the insulin sensitizing agent metformin. The insulin resistance of lean patients with the syndrome is debated. In this study, we will study the change in insulin resistance, metabolic and hormonal factors after 3 months of metformin treatment in lean PCOS women.

Condition Intervention
Polycystic Ovary Syndrome Drug: Metformin

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by Aarhus University Hospital Skejby:

Primary Outcome Measures:
  • Insulin resistance
  • Hormonal factors
  • Metabolic factors

Estimated Enrollment: 20

Ages Eligible for Study:   20 Years to 35 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • PCOS (Rotterdam criteria)
  • BMI < 27
  • No medication for 3 months

Exclusion Criteria:

  • Pregnancy
  • Lactation
  • Other endocrinologic disease
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00319293

Sponsors and Collaborators
Aarhus University Hospital Skejby
Aarhus University Hospital
Principal Investigator: Birgitta Trolle, MD Skejby University Hospital
  More Information Identifier: NCT00319293     History of Changes
Other Study ID Numbers: 160350-2
Study First Received: April 26, 2006
Last Updated: October 10, 2006

Additional relevant MeSH terms:
Polycystic Ovary Syndrome
Pathologic Processes
Ovarian Cysts
Ovarian Diseases
Adnexal Diseases
Genital Diseases, Female
Gonadal Disorders
Endocrine System Diseases
Hypoglycemic Agents
Physiological Effects of Drugs processed this record on August 18, 2017